BeyondSpring, Inc. develops innovative immuno-oncology cancer therapies with a robust pipeline from internal development and collaboration with the University of Washington in de novo drug discovery using an ubiquitination platform. BeyondSpring's lead asset, plinabulin, is in two phase 3 global clinical trials as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and the prevention of chemotherapy-induced neutropenia (CIN).